{"id":"W4290997231","doi":"10.1136/annrheumdis-2022-eular.2834","title":"POS0941 LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON‑RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Celgene; Gilead Sciences; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Certolizumab pegol; Ankylosing spondylitis; BASDAI; Internal medicine; Axial spondyloarthritis; Sacroiliitis; C-reactive protein; Placebo; Gastroenterology; Physical therapy; Adalimumab; Disease; Inflammation; Pathology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005581388,0.0002866165,0.0006510674,0.0002514744,0.0002638001,0.0007814279,0.0002535325,0.0007348757,0.001735779],"category_scores_gemma":[0.001475486,0.0001838589,0.00106778,0.0004817608,0.0003224254,0.0007459892,0.0003499697,0.0009368029,0.0003387809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003153852,"about_ca_system_score_gemma":0.0003919885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001118701,"about_ca_topic_score_gemma":0.002053863,"domain_scores_codex":[0.9995603,0.00009698515,0.00004877389,0.00009413991,0.00005468869,0.0001451246],"domain_scores_gemma":[0.9989373,0.0002319902,0.000451727,0.0000391606,0.00007555907,0.0002642968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03675871,0.0006180885,0.9345279,0.0002665158,0.001775355,0.0006461723,0.0001250865,0.0004452727,0.002093162,0.000148268,0.001360226,0.02123522],"study_design_scores_gemma":[0.000472912,0.004011655,0.9931932,0.00005380055,0.0004761136,0.0004061857,0.0001388798,0.0002928014,0.00009696039,0.0001061345,0.0007290149,0.00002244011],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959506,0.002204568,0.00003187586,0.0001571423,0.00007253263,0.000009203198,0.0005659956,0.000003430513,0.00100465],"genre_scores_gemma":[0.9981319,0.0004010933,0.00002196853,0.0001545774,0.00007272325,0.000009923567,0.0008742138,0.000001106182,0.0003324578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001735779,"threshold_uncertainty_score":0.005806744,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0198552243507414,"score_gpt":0.3017079740843017,"score_spread":0.2818527497335603,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}